Search

Shanxi Luan Refined Wax Co,.Ltd is a high-tech enterprise under Shanxi Lu'an Mining (Group) Co., Ltd., specializing in the research, development, production, and sales of refined paraffin wax, microcrystalline wax, specialty waxes, and wax-based functional materials. Leveraging the raw material advantages of coal indirect liquefaction by-products—wax—from Lu’an Group, the company has established a complete industrial chain spanning purification and refining of coal-based Fischer-Tropsch wax to deep processing of high-value-added wax-based chemicals. This aligns with national policy priorities for the refinement and high-end extension of coal chemical industry. The company’s core products include fully refined paraffin waxes (grades 52#–70#), semi-refined paraffin waxes (grades 60#–80#), H-series high-melting-point microcrystalline waxes, oxidized waxes, polyethylene wax emulsions, customized wax-based mold-release agents, and hot-melt adhesive-modified waxes. These products are widely applied across packaging, hot-melt adhesives, rubber protection, cosmetics, precision casting, and cable waterproofing. The company hosts a provincial-level enterprise technology center and holds four invention patents, including “A Method for Deep Refining of Coal-Based Fischer-Tropsch Wax.” It also participated in the revision of the national standard GB/T 1557-2021 “Paraffin Wax.” The company possesses the “National Industrial Product Production License” (for hazardous chemical organic products), third-level certification for safety production standardization, and ISO 9001 Quality Management System Certification (Certificate No.: 00122Q31258R1M). It has supplied customized wax-based composite additives to numerous leading domestic hot-melt adhesive and wire & cable enterprises, and since 2022, has exported microcrystalline wax products to Southeast Asian markets including Vietnam and Thailand. As a key supporting enterprise for wax-based new materials in Shanxi Province, it offers downstream manufacturing enterprises multi-dimensional collaboration, including standardized wax product supply, joint formula development, customized functional wax-based additives, and technical solutions.

Shanxi Jianlong Industrial Co., Ltd. is a full-process integrated steel enterprise controlled by Beijing Jianlong Heavy Industry Group Co., Ltd., specializing in ferrous metal smelting and rolling processing, with a strategic focus on the research, development, and manufacturing of high-value-added premium special steels. The company’s core products include hot-rolled deformed bars, hot-rolled round bars, H-beams, and premium special steel bars, which are widely applied in construction, machinery manufacturing, energy equipment, rail transit, and other sectors. It continuously extends its product portfolio toward differentiated areas such as HRB600E high-strength seismic-resistant rebars, bearing steels for wind-power applications, high-end gear steels, weathering and corrosion-resistant steels, and spring flat steels. Leveraging the integrated “intelligent steelmaking + controlled rolling and controlled cooling” process, the company has achieved digital coverage across all production lines, established a blast furnace digital twin system and a continuous casting AI-based surface inspection system, and been recognized as a Shanxi Province Intelligent Manufacturing Demonstration Project. It hosts a provincial-level enterprise technology center and the Shanxi Provincial Engineering Technology Research Center for High-Performance Construction Steels, holds over 260 authorized patents (including 47 invention patents), and has participated in the formulation and revision of 12 national and industry standards. In terms of certifications, the company complies with ISO 9001, ISO 14001, and ISO 45001 management system standards; holds the National Industrial Product Production License (Steel Products); has been rated as a Level-One Standardized Enterprise for Safety Production; has been designated a “Green Factory” by the Ministry of Industry and Information Technology (MIIT); and has completed ultra-low emission retrofitting, passing assessment and public announcement by the Ministry of Ecology and Environment. Representative collaborations include bulk supply of HRB600E rebars for key projects in the Xiong’an New Area; provision of specialized steel products for oil-and-gas pipelines under the China National Petroleum Pipeline Network Group Co., Ltd.; and supply of spring flat steels for rail transit applications to CRRC Group. Its customer base covers major central SOEs and regional leading enterprises such as China State Construction Engineering Corporation, China Railway Group Limited, Shaanxi Construction Group Co., Ltd., and Shanxi Construction Engineering Group Co., Ltd. Its business spans the North China, Northwest China, and East China regions, enabling it to deliver customized steel products, technical collaboration, and supply chain support for engineering construction, equipment manufacturing, and energy infrastructure development.

Shanxi Synthetic Biology Institute Co., Ltd. is a provincial-level key newly established research institution in Shanxi Province, jointly initiated by Shanxi University, platforms under the Shanxi Provincial State-owned Assets Supervision and Administration Commission, and multiple biotechnology enterprises. The institute focuses on tackling frontier technologies in synthetic biology and facilitating their industrialization and commercial translation. It collaborates with the National Experimental Teaching Demonstration Center for Biotechnology at Shanxi University and the State Key Laboratory of Clean and Efficient Utilization of Coal-Based Energy, jointly constructed by Shanxi Province and the Ministry of Science and Technology.

The company’s core business activities include: development of microbial gene-editing tools; construction of non-grain biomass-based chassis cells; design and optimization of biosynthetic pathways for natural products; directed evolution of enzymes; and green biological manufacturing of high-value chemicals. Its service domains encompass pharmaceutical intermediates, functional food ingredients, monomers for bio-based materials, and agricultural biological agents.

The company has established a pilot-scale verification platform with an annual capacity of 1,000 tons, possessing end-to-end technical capabilities spanning strain construction, pathway optimization, and pilot-scale scale-up. Its core achievements have supported pharmaceutical enterprises in upgrading enzymatic production processes for allulose. It holds 12 authorized invention patents, seven of which pertain to CRISPR-Cas12a-assisted multiplex gene circuit regulation technology. It has led or participated in formulating three group standards, including “Technical Specification for β-Nicotinamide Mononucleotide (NMN) Production via Microbial Fermentation.”

The company is certified under ISO 9001 Quality Management System and ISO 22000 Food Safety Management System. It holds a “Hygiene Permit for Disinfectant Product Manufacturing Enterprises” and has been recognized as a Shanxi Provincial Science and Technology-based Small and Medium-sized Enterprise.

Currently, its service region primarily covers biomanufacturing enterprises and university research teams in North China and East China. Collaborating institutions include the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, and the State Key Laboratory of Biochemical Engineering at East China University of Science and Technology. The company offers diversified collaboration models to the industry, including technology R&D, process optimization, pilot-scale verification, and joint standard development.

Shanxi Fuma Carbon Materials Technology Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and application of advanced carbon materials. Positioned as a technology-driven startup, the company focuses on pilot-scale verification and industrialization implementation of key segments for lithium-ion battery anode materials. Its core business encompasses R&D and pilot-scale development of high-performance spherical graphite, isotropic graphite, isostatic graphite, and specialized carbon/carbon composite materials for lithium-ion battery anodes. Its technical pathways cover purification of natural flake graphite, spheroidization and shaping, surface coating, and optimization of high-temperature graphitization processes; certain production lines possess continuous, low-energy-consumption graphitization capabilities. Leveraging the Yangqu Industrial Park facility—a pilot-scale platform with an annual capacity of 3,000 tons of lithium-ion battery anode material precursors and supporting graphitization—the company has passed energy conservation review and obtained approval for its specialized safety facility design report, and completed environmental impact assessment (EIA) filing (Jin Huan Shen Han [2023] No. 187). The company has been certified as a High-Tech Enterprise and holds ISO 9001:2015 Quality Management System Certification (Certificate No.: 00122Q41234XXX) and GB/T 29490-2013 Intellectual Property Management System Certification. Product testing reports are issued by the National Carbon–Graphite Materials Quality Supervision and Inspection Center (Shenyang), covering critical parameters including tap density, specific surface area, ash content (≤500 ppm), and control of impurity elements such as Fe, Ca, and Ni. In collaboration with the Institute of Coal Chemistry, Chinese Academy of Sciences (Shanxi), the company is jointly developing high-capacity, long-cycle-life spherical graphite anode materials; related findings have been published in the journal New Carbon Materials (DOI: 10.1016/j.carbon.2024.05.012). Currently, the company primarily engages in pilot-scale verification, customer sample submission, and technical cooperation, serving small- and medium-sized lithium-ion battery material enterprises and research institutions concentrated in North China. It offers customized pilot-scale support, joint technology development, process optimization consulting, and material performance validation services to upstream and downstream industry chain partners.

Shandong Yitai Bocheng Chemical Technology Co., Ltd. is a high-tech enterprise specializing in the fine chemical industry, jointly established by Shandong Yitai Group Co., Ltd. and the Bocheng Chemical Technology Team. The company focuses on research, development, production, and application services for novel environmentally friendly water treatment chemicals, electronic-grade specialty chemicals, and high-end functional auxiliaries. Its core products include the ITB-801 series of phosphorus-free, nitrogen-free green scale and dispersion inhibitors and electronic-grade sodium hypophosphite, which are widely applied in industrial circulating water systems, oilfield produced water treatment, chemical park water treatment, and electronic material purification. These products have achieved large-scale application in 12 major industrial enterprises, including Sinopec Shengli Oilfield and Wanhua Chemical Yantai Industrial Park. Third-party testing indicates that its products can enhance COD removal efficiency by 18.7% and reduce phosphorus discharge to nearly zero. The enterprise possesses robust technical R&D capabilities, having been granted four utility model patents and two invention patents by the China National Intellectual Property Administration, covering key technologies such as automatic dosing devices for corrosion and scale inhibitors and preparation methods for composite water treatment agents containing phosphonic-carboxylic acid structures. It has obtained ISO 9001:2015 Quality Management System Certification and holds both the “Work Safety Production License” (Lü WH An Xu Zheng Zi [2023] No. 030228) and the “National Industrial Product Production License” (XK13-014-00126), with authorization covering the full range of water treatment agent production. Its annual production project for 12,000 tons of electronic-grade sodium hypophosphite and associated purification facilities has been included in Zibo City’s 2023 Major Industrial Project Database and has passed final acceptance inspection; the company is designated by Huantai County as a “Key Cultivation Enterprise for New Pharmaceutical and New Material Industry Chains.” Currently, it primarily serves customers in North and East China, offering cooperative models including customized product R&D, OEM/ODM manufacturing, integrated technical solutions, and long-term supply services, supporting collaborative innovation and industrial implementation tailored to specific application scenarios.

Shandong Ruisheng Carbon Materials Technology Co., Ltd. is a high-tech enterprise specializing in the research, development, and industrialization of advanced carbon-based functional materials. The company focuses on the “graphene and carbon nanotube material manufacturing” segment within China’s national strategic emerging industries, with core expertise in the technological development, engineering-scale transformation, and large-scale application of carbon-based composite anode materials for lithium-ion batteries. Its primary business encompasses the R&D, production, and sales of graphene materials, carbon nanotubes, and carbon-based composite materials, as well as the technological development, technical services, and testing consultancy related to novel energy storage materials and lithium battery anode materials. Leveraging an independently owned intellectual property system, the company has secured authorization for five utility model patents; among them, the patent titled “Graphene–Carbon Nanotube Synergistically Enhanced Lithium Battery Anode Composite Material and Preparation Method” represents a key technological breakthrough, while one invention patent is currently undergoing substantive examination. The company holds ISO 9001:2015 Quality Management System certification and Level-3 Safety Production Standardization (Light Industry) qualification, with its certified scope covering the full-chain R&D and production of lithium battery carbon-based anode materials. As the implementing entity of the Zibo Municipal Science and Technology Innovation Development Program, the company’s lead project—the “Pilot Production Line for High-Conductivity Graphene-Modified Silicon-Carbon Anode”—has received municipal special funding support. It has jointly established the “Carbon-Based Energy Storage Materials Joint Laboratory” with Shandong University of Technology to collaboratively address challenges in improving initial Coulombic efficiency and optimizing cycling stability. In 2025, the company successfully delivered ton-scale shipments of carbon nanotube conductive slurries to domestic power lithium battery manufacturers and passed comprehensive performance verification. Based in Shandong Province and serving the entire country, the company has developed differentiated technical capabilities in carbon material structural modulation, conductive slurry preparation processes, and anode material engineering-scale implementation, offering battery manufacturers, materials enterprises, and research institutions diversified collaboration pathways—including customized R&D partnerships, technology transfer and commercialization, pilot-scale validation, and bulk supply.

Shandong Rike Rubber And Plastic Technology Co.,Ltd is a national high-tech enterprise specializing in the research, development, production, and application of polymer materials. The company focuses on rubber additives, functional elastomer/plastic masterbatches, thermoplastic elastomers (TPE/TPV), and modified specialty engineering plastics. Its core businesses include rubber additives such as anti-scorch agent CTP and accelerator NS, as well as high-performance materials like the TPE-S series of thermoplastic elastomers. Its products are widely applied in tire manufacturing, automotive components, rail transit sealing systems, construction waterproofing materials, and cushioning and protective solutions for premium consumer electronics. Leveraging the Shandong Province “One Enterprise, One Technology” R&D Center and the Weifang City Engineering Technology Research Center for Elastomer & Plastic Functional Materials, the company holds 12 authorized invention patents and over 30 utility model patents. Among these, the invention titled “Sulfur-Free Eco-Friendly Rubber Anti-Scorch Agent and Preparation Method Thereof” (Patent No.: ZL201910287654.1) has been designated as a technology transfer project under the Shandong Provincial Key R&D Program. The company is certified under ISO 9001, ISO 14001, and IATF 16949 quality management systems; its key products have obtained REACH registration, RoHS compliance declarations, and Green Product Certification from the China Petroleum and Chemical Industry Federation. It has delivered customized rubber additive solutions to leading tire manufacturers including Zhongce Rubber Group, Triangle Group, and Linglong Tire; participated in the development of high-damping rubber materials used in fasteners for the Beijing–Zhangjiakou High-Speed Railway track system; and achieved mass production application of its TPE-S series materials in cushioning structural components for certain wearable devices produced by Xiaomi and Huawei. Its services cover East China, North China, and South China regions, with primary customers concentrated among Tier-1 automotive suppliers and large-scale rubber product enterprises. It collaborates with industry clients through material R&D co-development, formulation optimization, customized manufacturing, and technical application support.

Shandong Minghoudé New Energy Technology Co., Ltd. is a comprehensive service provider focusing on the construction of new power systems, specializing in distributed photovoltaics (PV), industrial and commercial energy storage, integrated PV-storage-charging solutions, and county-level holistic PV development initiatives. The company’s core businesses encompass solar and wind power generation technical services; energy storage system integration and operation & maintenance (O&M); manufacturing and sales of primary equipment for new energy; supply of intelligent power transmission, distribution, and control equipment; contract energy management; research and development of energy-saving and carbon emission reduction technologies; and full-lifecycle services for PV power generation projects (including development, construction, and O&M). Leveraging its proprietary “Minghoudé Intelligent Control Cloud Platform” and multiple intellectual property rights—including three invention patents, twelve utility model patents, and eight software copyrights—the company possesses millisecond-level data acquisition capabilities and closed-loop AGC/AVC response capabilities, and has been integrated into the Shandong Provincial Power Dispatching Center’s automation system. The company holds a Class-III License for Installation (Maintenance, Testing) of Electric Power Facilities, ISO 9001/14001/45001 management system certifications, has been selected as one of Shandong Province’s “Specialized, Refined, Distinctive, and Innovative” SMEs for 2024, and has passed the Level-II Standardization Review for Safety Production in New Energy Power Generation Enterprises. Representative projects include the Weiqiao Zouping Park 12 MW / 24 MWh User-Side Energy Storage Peak-Shaving Demonstration Project; the First-Phase Engineering of Yinan County’s Holistic PV Initiative (86 MW); and Wanhua Chemical’s integrated energy solution featuring “PV-Storage Microgrid + Green Electricity Traceability.” The company’s business covers the entire Shandong Province and extends to regional project centers established in Hebei, Henan, and Jiangsu Provinces. It provides diversified cooperation models—including distributed energy development, energy storage system construction, intelligent O&M outsourcing, green electricity and green certificate support, and carbon management—for government platforms, industrial parks, large-scale industrial enterprises, and energy investors.

Shandong Luoxin Pharmaceutical Group Hengxin Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Shandong Luoxin Pharmaceutical Group Co., Ltd. (002793.SZ), engaged in the production of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company is positioned as a GMP-compliant API manufacturing platform integrating R&D, production, quality management, and compliant export operations, supporting the Group’s strategies of “API + formulation integration” and “green intelligent manufacturing upgrade.” Its core product portfolio comprises over ten API varieties, primarily in the anti-infective category (e.g., sodium cefuroxime, cefixime, azithromycin, clarithromycin) and cardiovascular therapeutics. Products mainly secure the internal formulation supply chain of Luoxin Pharmaceutical and are supplied to compliant domestic and international customers; exports cover India, Southeast Asia, the Middle East, Latin America, and other regions. The company maintains a quality management system compliant with ICH Q7 requirements and has completed API registration with China’s National Medical Products Administration (NMPA) (Registration No. Y20220001289, etc.), passed the U.S. FDA cGMP on-site inspection (cephalosporin API workshop inspection completed in June 2023), and obtained multiple European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of a Suitability of the Monograph to the Composition of the Substance (CEPs). It also holds ISO 9001, ISO 14001, and ISO 45001 certifications and was designated in 2022 as a Shandong Province “Specialized, Refined, Distinctive, and Innovative” (SRDI) small- and medium-sized enterprise. Technologically, the company has established an intelligent continuous manufacturing line for cephalosporin APIs (commissioned in 2024) and continues advancing green synthetic process optimization and continuous flow technology applications; its project titled “Key Green Synthesis Technologies and Industrialization of Cephalosporin Antibiotics,” supported by these achievements, received the Second Prize of the 2023 Shandong Provincial Science and Technology Progress Award (Luoxin Pharmaceutical being the primary completing entity). Collaboration opportunities include customized API development and large-scale supply, joint green process optimization, international regulatory registration support, and contract manufacturing services compliant with cGMP/CEP/FDA standards.

Shandong Luoxin Pharmaceutical Group Co., Ltd. (Stock Code: 002793.SZ) is an integrated chemical pharmaceutical enterprise engaged in drug research and development, manufacturing, and marketing, focusing on major disease areas including gastrointestinal disorders, oncology, anti-infectives, respiratory diseases, and cardiovascular conditions. The Company’s core businesses encompass chemical active pharmaceutical ingredients (APIs), chemical finished dosage forms, biosimilars, and traditional Chinese medicine (TCM) preparations. Its key products include Lansoprazole for Injection (the first domestically approved product to pass consistency evaluation), Tegoprazan Tablets (China’s first approved potassium-competitive acid blocker), Ambroxol Hydrochloride Oral Solution (ranked No. 1 in retail pharmacy sales nationwide), Ceftriaxone Sodium for Injection, and Budesonide Suspension for Inhalation (LX-03), among others. Leveraging two national high-tech enterprises, one national enterprise technology center, one postdoctoral research workstation, and multiple provincial engineering technology research centers, the Company has undertaken ten national “Major New Drug Creation” Science and Technology Major Projects and received one Second Prize of the National Science and Technology Progress Award. As of the end of 2024, it holds 236 valid invention patents and has filed 32 PCT international patent applications; it has over 100 ongoing R&D projects, including LY01011, an innovative drug that has entered Phase II clinical trials. The Company operates integrated API and formulation manufacturing bases compliant with China’s Good Manufacturing Practice (GMP), U.S. FDA current GMP (cGMP), and European Directorate for the Quality of Medicines & HealthCare (EDQM) standards. Its three major production bases—Linyi, Hengxin, and Xiamen—have all obtained certification from China’s National Medical Products Administration (NMPA); certain workshops have also passed on-site inspections by the U.S. FDA. All production units are incorporated into China’s national drug traceability system, and the Company has achieved certification under ISO 9001, ISO 14001, and ISO 45001 management systems. Its products are distributed across all 31 provinces, autonomous regions, and municipalities directly under the Central Government of China, as well as Hong Kong and Macao, achieving over 85% coverage in primary healthcare institutions and over 70% coverage in Grade III hospitals. More than 20 products have obtained EDQM Certificates of a Suitability of Active Substance, FDA Drug Master File (DMF) registrations, or approvals from Korea’s Ministry of Food and Drug Safety (MFDS). In 2023, export revenue to Southeast Asia, the Middle East, Latin America, and other regions increased by 22.6% year-on-year. The Company offers diversified collaboration opportunities to domestic and international pharmaceutical enterprises, including technical cooperation, joint overseas regulatory registration support, customized development of APIs and formulations, generic drug consistency evaluation support, and collaborative clinical development of innovative drugs.